News

In children with cystic fibrosis (CF) treated with Orkambi (ivacaftor/lumacaftor), the levels of the medication reached in the blood depend on how much the children weigh and how well their liver is working, a new study discovered. These findings offer insights into how to best adjust doses of the approved…

People with cystic fibrosis (CF) can have abnormal levels or metabolism of three “essential nutrients” — vitamin D, calcium, and phosphate — even when using pancreatic enzyme replacement therapy (PERT) and taking dietary supplements, a small study suggests. “The findings of this study have many practical implications in…

Intellia Therapeutics and ReCode Therapeutics are joining forces to develop new genomic medicines for people with cystic fibrosis (CF). The companies said initial research will focus on patients who have “limited or no treatment options available.” The ultimate goal is to create a new genomic medicine that…

Certain markers of inflammation found deep in the lungs of children with cystic fibrosis (CF) can help predict how bronchiectasis will worsen over time, offering insights for better treatment and care, a study suggests. Among other markers, higher levels of interleukin-8 (IL-8), a signaling…

Between 2011 and 2021, improving lung function and better survival rates were consistently seen among people with cystic fibrosis (CF) in Europe, particularly in wealthier countries and with the introduction of new treatments, according to a study that tracked more than 45,000 CF patients across the continent over the…

Up to almost 30% of teenagers and adults with cystic fibrosis (CF) in the U.S. have smoked marijuana and/or cannabidiol (CBD), one of the active components of cannabis, according to an online survey. Use of e-cigarettes and traditional cigarettes was just as common among them.

The frequent use of aminoglycosides — a class of antibiotics commonly used to help treat lung infections in people with cystic fibrosis (CF) — has been linked to an increased risk of hearing problems in CF patients, starting in childhood, according to a new pediatric study in Belgium. The…

A new triple-combination CFTR modulator therapy for cystic fibrosis (CF) — vanzacaftor, tezacaftor and deutivacaftor — outperformed the approved therapy Trikafta (elexacaftor/tezacaftor/ivacaftor) at reducing sweat chloride levels in Phase 3 trials. The new “vanza triple” combo was similar to Trikafta at maintaining…